Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma

被引：21

作者：

Einsele, H. ^{[1
]}

Knop, S. ^{[1
]}

Vogel, M. ^{[2
]}

Mueller, J. ^{[3
]}

Kropff, M. ^{[4
]}

Metzner, B. ^{[5
]}

Langer, C. ^{[6
]}

Sayer, H. ^{[7
]}

Jung, W. ^{[8
]}

Duerk, H. A. ^{[9
]}

Salwender, H. ^{[10
]}

Wandt, H. ^{[11
]}

Bassermann, F. ^{[12
]}

Gramatzki, M. ^{[13
]}

Roesler, W. ^{[14
]}

Wolf, H-H ^{[15
]}

Brugger, W. ^{[16
]}

Engelhardt, M. ^{[17
]}

Fischer, T. ^{[18
]}

Liebisch, P. ^{[6
]}

Straka, C. ^{[19
]}

机构：

[1] Julius Maximilians Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[2] Janssen Cilag GmbH, Neuss, Germany

[3] Acromion GmbH, Frechen, Germany

[4] Univ Klinikum Munster, Munster, Germany

[5] Klinikum Oldenburg Klin Onkol & Hamatol, Oldenburg, Germany

[6] Univ Klinikum Ulm, Zentrum Innere Med, Ulm, Germany

[7] Univ Hosp Jena, Jena, Germany

[8] Onkol Univ Med Gottingen, Gottingen, Germany

[9] St Marien Hosp Hamm Knappenstr, Hamm, Germany

[10] Asklepios Klin Altona, Hamburg, Germany

[11] Med Klin 5 Hamatol & Onkol, Nurnberg, Germany

[12] Tech Univ Munich, Med Klin, Munich, Germany

[13] Univ Klinikum Schleswig Holstein, Kiel, Germany

[14] Univ Klinkum Erlangen, Erlangen, Germany

[15] Univ Hosp Halle, Halle, Saale, Germany

[16] Schwarzwald Baar Klinikum, Villingen Schwenningen, Germany

[17] Univ Freiburg, Freiburg, Germany

[18] Otto von Guericke Univ, Magdeburg, Germany

[19] Schon Klin Starnberger See, Berg, Germany

来源：

LEUKEMIA | 2017年 / 31卷 / 06期

关键词：

STEM-CELL TRANSPLANTATION; INDUCTION; THERAPY; PHASE-3;

D O I：

10.1038/leu.2017.83

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1463 / 1466

页数：5

共 50 条

[1] Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma
Qin Yazhen
Lu Jin
Bao Li
Zhu Honghu
Li Jinlan
Li Lingdi
Lai Yueyun
Shi Hongxia
Wang Yazhe
Liu Yanrong
Jiang Bin
Huang Xiaojun
CHINESE MEDICAL JOURNAL, 2014, 127 (09) : 1666 - 1671
[2] Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Jackson, Graham H.
Davies, Faith E.
Pawlyn, Charlotte
Cairns, David A.
Striha, Alina
Collett, Corinne
Waterhouse, Anna
Jones, John R.
Kishore, Bhuvan
Garg, Mamta
Williams, Cathy D.
Karunanithi, Kamaraj
Lindsay, Jindriska
Wilson, Jamie N.
Jenner, Matthew W.
Cook, Gordon
Kaiser, Martin F.
Drayson, Mark T.
Owen, Roger G.
Russell, Nigel H.
Gregory, Walter M.
Morgan, Gareth J.
LANCET HAEMATOLOGY, 2019, 6 (12): : E616 - E629
[3] Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT
Syed, Yahiya Y.
DRUGS, 2017, 77 (13) : 1473 - 1480
[4] Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis
Avet-Loiseau, Herve
Ludwig, Heinz
Landgren, Ola
Paiva, Bruno
Morris, Chris
Yang, Hui
Zhou, Kefei
Ro, Sunhee
Mateos, Maria-Victoria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (01) : E30 - E37
[5] Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
Costa, Luciano J.
Chhabra, Saurabh
Medvedova, Eva
Dholaria, Bhagirathbhai R.
Schmidt, Timothy M.
Godby, Kelly N.
Silbermann, Rebecca
Dhaka, Binod
Bal, Susan
Gid, Smith
D'Souza, Anita
Hall, Aric
Hardwick, Pamela
Omel, James
Cornell, Robert F.
Had, Parameswaran
Callander, Natalie S.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (25) : 2901 - +
[6] Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
Heaney, Jennifer L. J.
Campbell, John P.
Iqbal, Gulnaz
Cairns, David
Richter, Alex
Child, J. Anthony
Gregory, Walter
Jackson, Graham
Kaiser, Martin
Owen, Roger
Davies, Faith
Morgan, Gareth
Dunn, Janet
Drayson, Mark T.
LEUKEMIA, 2018, 32 (08) : 1727 - 1738
[7] Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
Avet-Loiseau, Herve
Fonseca, Rafael
Siegel, David
Dimopoulos, Meletios A.
Spicka, Ivan
Masszi, Tamas
Hajek, Roman
Rosinol, Laura
Goranova-Marinova, Vesselina
Mihaylov, Georgi
Maisnar, Vladimir
Mateos, Maria-Victoria
Wang, Michael
Niesvizky, Ruben
Oriol, Albert
Jakubowiak, Andrzej
Minarik, Jiri
Palumbo, Antonio
Bensinger, William
Kukreti, Vishal
Ben-Yehuda, Dina
Stewart, A. Keith
Obreja, Mihaela
Moreau, Philippe
BLOOD, 2016, 128 (09) : 1174 - 1180
[8] Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma
Ghosh, Nilanjan
Ye, Xiaobu
Ferguson, Anna
Huff, Carol Ann
Borrello, Ivan
BRITISH JOURNAL OF HAEMATOLOGY, 2011, 152 (05) : 593 - 599
[9] Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials
Straka, Christian
Knop, Stefan
Vogel, Martin
Mueller, Juergen
Kropff, Martin
Metzner, Bernd
Langer, Christian
Sayer, Herbert
Jung, Wolfram
Duerk, Heinz A.
Salwender, Hans
Wandt, Hannes
Bassermann, Florian
Gramatzki, Martin
Roesler, Wolf
Wolf, Hans-Heinrich
Brugger, Wolfram
Fischer, Thomas
Liebisch, Peter
Engelhardt, Monika
Einsele, Hermann
EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 103 (03) : 255 - 267
[10] The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review
Gagelmann, Nico
Kroeger, Nicolaus
ANNALS OF HEMATOLOGY, 2021, 100 (02) : 405 - 419

← 1 2 3 4 5 →